Thijo Jeroen N Hiltermann

23PUBLICATIONS
159CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Commercial lawCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Aug 10, 2026
Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.

|Jul 28, 2026
The Association and Predictive Value of Nutritional and Inflammatory Biomarkers in Advanced Non-Small Cell Lung Cancer Response to Immune Checkpoint Inhibitors.

|Apr 17, 2026
Sex-based differences in effectiveness of immune checkpoint inhibitors in the treatment of advanced non-small-cell lung cancer: systematic review and meta-analysis.

|Mar 11, 2026
Association of CT-assessed sarcopenia and the development of immune-related adverse events and overall survival: a multistate survival analysis.

Erick Suazo-Zepeda, Marjolein A Heuvelmans, Douwe Postmus

|Jan 08, 2026
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis.

Mariano Provencio, Mark M Awad, Jonathan D Spicer

|Sep 10, 2025
Upfront whole blood transcriptional patterns in patients receiving immune checkpoint inhibitors associate with clinical outcome.

S Hone Lopez, S Loipfinger, A Bhattacharya

Pageof 4

Frequent Collaborators

9 joint publications

Harry Jm Groen

5 joint publications

Ed Schuuring

5 joint publications

Wim Timens

3 joint publications

Léon C van Kempen